Autophagy and phospholipidosis pathway assays

• US 9,250,249 B2
• Filed: 09/14/2009
• Issued: 02/02/2016
• Est. Priority Date: 09/08/2008
• Status: Active Grant

• Current Assignee: Enzo Biochem Incorporated
• Original Assignee: Enzo Biochem Incorporated
• Inventors: Patton, Wayne Forrest, Coleman, Jack, Xiang, Yuejun, Pande, Praveen, Li, Zaiguo
• Primary Examiner(s): BROOKS, CLINTON A
• Application Number:
  US12/584,958
• Publication Number:
  US 20100093004A1
• Time in Patent Office: 2,332 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 2800/02 Nutritional disorders
• CPC Class Codes: G01N 2800/04 Endocrine or metabolic disorders
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5076 involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
• CPC Class Codes: G01N 33/582 with fluorescent label
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G01N 33/94 involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Abstract

Provided are assays useful for detecting and monitoring autophagy and phospholipidosis, including the progression of lysosomal storage diseases. Drugs and treatments for lysosomal storage diseases can be monitored for effectiveness in lysosomal storage disease conditions. Drug candidates and suspected toxic agents can also be screened for toxicity to cells, tissues and organs. Also provided are methods for distinguishing between phospholipidosis activators and autophagy pathway perturbation agents.

Claims

1. A method of detecting the presence of a lysosomal storage disease in a subject comprising the steps of:

(a) obtaining a sample containing cells from said subject;

(b) contacting said sample with a cationic amphiphilic tracer compound that localizes to a vacuole in a cell selected from

2. The method of claim 1, wherein the subject is known to have a lysosomal storage disease based upon previous genetic or metabolic testing.

3. The method of claim 2, further comprising comparing the excess above normal accumulation of vacuoles in the cells in the sample with the accumulation of vacuoles in cells of a prior sample obtained from the subject.

4. The method of claim 3, wherein the subject has been treated with a drug or remedy used to manage, treat or cure the lysosomal storage disease between the prior sample and the sample obtained in step (a).

5. The method of claim 3, wherein the subject has been treated with a drug candidate between the prior sample and the sample obtained in step (a).

6. The method of claim 3, wherein the subject has been exposed to a suspected toxic agent between the prior sample and the sample obtained in step (a).

7. The method of claim 1, further comprising the steps of (a′

) providing a reference sample of normal cells from a subject known not to have lysosomal storage disease;

(b′

) contacting said sample of normal cells with the same cationic amphiphilic tracer compound of step (b); and

(c′

) comparing the accumulation of vacuoles in the sample obtained from the subject known or suspected of having a lysosomal storage disease with the accumulation in said reference sample of normal cells.

8. The method of claim 1, wherein said subject is a mammal.

9. The method of claim 1, wherein said mammal is human.

10. The method of claim 1, wherein the cationic amphiphilic tracer compound is

11. The method of claim 1, wherein the cationic amphiphilic tracer compound is

12. The method of claim 1, wherein the cationic amphiphilic tracer compound is

13. The method of claim 1, wherein the cationic amphiphilic tracer compound is

14. A method of detecting Fabry disease, phospholipodosis, or lysosomal perturbation in U2OS human cells comprising the steps of:

(a) obtaining a sample containing said cells;

(b) contacting said sample with the cationic amphiphilic tracer compound having the structure

16. The method of claim 14 or claim 15, wherein the lysosomal perturbation is selected from phospholipidosis, expansion in the lysosomal compartment, vacuolar inclusions, vacuolation and disruption of trafficking in the autophagy pathway.

15. A method of detecting lysosomal perturbation in HeLa cells comprising the steps of:

(a) obtaining a sample containing said cells;

(b) contacting said sample with a cationic amphiphilic tracer compound selected from

17. A method of detecting Niemann-Pick disease in human cells comprising the steps of:

(a) obtaining a sample containing said cells;

(b) contacting said sample with the cationic amphiphilic tracer compound having the structure